-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -...
Perpetual Medicines announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for pe...
Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million Biologics Test...
A wave of respiratory illnesses, accompanied by alarming clusters of pneumonia cases, has inundated hospitals in northern China, sparking deep concerns abo...
With a steadfast dedication of 22 years to advancing the fundamental technologies of raw materials, reagent and instrument, Fapon strives to empower the gl...
Partnership agreement signed on 22 November to broaden distribution and promotion of cough and cold brands such as Shidagong, Gelite and Ruike in China&n...
The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...
"The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. ...
U.S. approval of FRUZAQLA triggers first milestone payment from Takeda of US$35 million and royalties on net sales HUTCHMED (China) Limited (Nasdaq/AIM:HC...
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...
Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...
The co-primary endpoints of the LIBRA trial were mite eradication (mite density of 0 mites per lash) and complete collarette cure (collarette score of 0) a...
Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing ...
Everest Medicines announced that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administratio...
© 2023 Biopharma Boardroom. All Rights Reserved.
